William Blair initiated coverage of Kalaris Therapeutics (KLRS) with an Outperform rating and $21 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLRS:
William Blair initiated coverage of Kalaris Therapeutics (KLRS) with an Outperform rating and $21 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLRS: